RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Clinical trials for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T shot aims to fight blood cancer without removing cells
Disease control Not yet recruitingThis early study tests a new treatment called DIT101 for people with blood cancers that have come back or stopped responding to other treatments. DIT101 is a special therapy given through a vein that helps the body make its own cancer-fighting cells, without needing to take cells…
Matched conditions: RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for tough blood cancers: BT02 drug trial launches
Disease control Not yet recruitingThis study tests a new drug called BT02 in people with blood cancers (leukemia, lymphoma, or multiple myeloma) that have returned or not improved with standard treatments. About 116 adults aged 18 to 70 will receive the drug by IV every 2-3 weeks for up to 2 years. The main goals…
Matched conditions: RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Biotroy Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:04 UTC